HCA
VNDA icon

Harbor Capital Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Harbor Capital Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$315K Sell
51,421
-555
-1% -$3.63K 0.02% 581
2026
Q1 		$359K Buy
+51,976
New +$401K 0.03% 539

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harbor Capital Advisors's VNDA Position: Q2 2026 in Review

Harbor Capital Advisors reduced its Vanda Pharmaceuticals (VNDA) stake by 1.1% in Q2 2026, selling an estimated $3.63K and leaving 51,421 shares worth $315K. The position accounts for 0.02% of the portfolio, ranked #581.

Harbor Capital Advisors first reported a position in VNDA in Q1 2026 and has held it in 2 quarters since. The position peaked at $359K in Q1 2026. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Harbor Capital Advisors held 51,421 shares of Vanda Pharmaceuticals worth $315K as of Q2 2026.
  • Harbor Capital Advisors sold 555 Vanda Pharmaceuticals shares in Q2 2026, an estimated $3.63K.
  • Vanda Pharmaceuticals made up 0.02% of Harbor Capital Advisors's portfolio in Q2 2026, its #581 holding.
  • Harbor Capital Advisors first reported a position in Vanda Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Harbor Capital Advisors's Vanda Pharmaceuticals position peaked at $359K in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.